Abstract:OBJECTIVE:To explore the effects of ursodeoxycholic acid (UDCA) on the fluidity of hepatic plasma membrane, glutathione concentration in liver, hepatic estrogen receptors and progesterone receptors in pregnant rats with ethinylestradiol and progesterone induced intrahepatic cholestasis. METHODS:sixty clean SD pregnant rats were selected and divided into three groups at random. Since the 13th day of pregnancy after taking blood, normal group was injected subcutaneously with refined vegetable oil 2.5 ml x kg(-1) x d(-1). Control group and treatment group were injected subcutaneously with the solution of progesterone 75 mg x kg(-1) x d(-1) and 17-alpha-ethynylestradio 1.25 mg x kg(-1) x d(-1) till the 17th day. Since the 17th day control group, normal group were fedwish 0.9% natriichloridi solution 5 ml x kg(-1) x d(-1); Treatment group was fedwish UDCA 50 mg x kg(-1) x d(-1) every day. On the 21th day, all rats were killed. Then the livers were collected for study. Membrane fluidity was measured by fluorescence polarization using 1,6-diphenyl-1,3,5-hexatriene (DPH) as a probe. Glutathione concentration was measured by 5,5'-dithionbis (2-nitrobenzoic acid) (DTNB). Estrogen receptors and progesterone receptors were measured by flow cytometry. RESULTS:(1) Hepatic plasma membrane fluidity and glutathione (GSH) concentration: significantly lower level of GSH concentration and higher fluorescence polarization (P) were detected in control group (GSH: 1.13 +/- 0.03, P: 0.149 +/- 0.008) in comparison with normal group (GSH: 2.11 +/- 0.07, P: 0.132 +/- 0.004, P < 0.05). However, Significantly higher level of GSH concentration and lower fluorescence polarization were detected in treatment group (GSH: 1.82 +/- 0.04, P: 0.141 +/- 0.006) in comparison with control group (P < 0.05). The level of GSH concentration and fluorescence polarization were no difference between treatment group and normal group. Hepatic estrogen receptors (ER) and progesterone receptors (PR): The expression of ER and PR in control group (ER: 89.4 +/- 8.4, PR: 112.3 +/- 11.6) were higher than that of other two groups (P < 0.05). The expression of ER and PR in treatment group (ER: 56.4 +/- 7.5, PR: 70.1 +/- 9.3) were lower than that of control group (P < 0.05). But there was no difference between treatment group and normal group (ER: 39.5 +/- 7.3, PR: 59.6 +/- 7.4; P > 0.05). CONCLUSION:Ursodeoxycholic acid may be effective drug in treatment intrahepatic cholestasis of pregnancy.

Effects of Ursodeoxycholic Acid on Intrahepatic Cholestasis in Rats

Beneficial effects of UDCA and norUDCA in a rodent model of steatosis are linked to modulation of GPBAR1/FXR signaling

Effect of compound ursodeoxycholic acid oral liquid on cholestatic hepatitis in rats

The effect of ursodeoxycholic acid on oxidative stress level and DNase activity in rat liver after bile duct ligation

Multicenter Study of Ursodeoxycholic Acid on Patients of Severe Chronic Hepatitis with Cholestasis

Effects of Ursodeoxycholic Acid on Hepatic Na+-K+-ATPase, Hepatic Function, and Pathohistology in Pregnant Rats with 17-Α-ethinylestradiol and Progesterone Induced Intrahepatic Cholestasis

Effects of Compound Ursodeoxycholic Acid Oral Liquid on Hepatic Fibrosis in Rats

The role of Ursodeoxycholic acid in non-alcoholic steatohepatitis: a systematic review

[Effects of Ursodeoxycholic Acid on the Liver Plasma Membrane Fluidity, Hepatic Glutathione Concentration, Hepatic Estrogen Receptors and Progesterone Receptors in Pregnant Rats with Ethinylestradiol and Progesterone Induced Intrahepatic Cholestasis].

The Clinical study on therapy of chronic hepatitis B with severe cholestasis applied by ursodeoxycholic Acid

Effect of ursodeoxycholic acid and olynicate and naphthylactic acid on chronic hepatitis B and intrahepatic cholestasis

Effect of Compound Ursodeoxycholic Acid Oral Liquid on Alcoholic Fatty Liver Disease in Rats

Effect of Ursodeoxycholi acid on liver cirrhosis with hepatitis B

Effect of ursodeoxycholic acid administration after liver transplantation on serum liver tests and biliary complications: a randomized clinical trial.

Ursolic Acid Alleviates Cholestasis by Regulating Nrf2- UGT2B7/BSEP/MRP2 Pathway in Vivo and in Vitro

Randomised post-test-only study of glutathione and ursodeoxycholic acid combination therapy on liver function in cholestasis-induced rats

Therapeutic Effect of Ursodeoxycholic Acid on Early-Stage Primary Biliary Cirrhosis.

A high-dose of ursodeoxycholic acid treatment alleviates liver inflammation by remodeling gut microbiota and bile acid profile in a mouse model of non-alcoholic steatohepatitis

Ursodeoxycholic acid for nonalcoholic steatohepatitis.

Efficacy and Safety of Tauroursodeoxycholic Acid in the Treatment of Liver Cirrhosis: A Double-Blind Randomized Controlled Trial

Effect of post-liver transplantation administration of ursodeoxycholic acid on serum liver tests and biliary complications: a randomized clinical trial